Tango Therapeutics Inc
NASDAQ:TNGX
Tango Therapeutics Inc
NASDAQ:TNGX
Price:
7.6 USD
3.97%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
TNGX
stock under the Base Case scenario is
3.49
USD.
Compared to the current market price of 7.6 USD,
Tango Therapeutics Inc
is
Overvalued by 54%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TNGX
Relative Value
Base Case
3.49
USD
Overvaluation 54%
Valuation Multiples
Multiples Across Competitors
TNGX Competitors Multiples
Tango Therapeutics Inc Competitors
Tango Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
776.7m USD | 21.3 | -7.6 | -3.9 | -3.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.4B USD | 5.3 | 59.2 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167B USD | 5.7 | 44.4 | 18.7 | 30.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.4B USD | 11.2 | 30.5 | 24.6 | 25.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 8.3 | 28.1 | 22.8 | 25.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.3B USD | 3.1 | 174.2 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.1B USD | 9.5 | -8.2 | -9 | -8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33B USD | 3.4 | 28.3 | 14.4 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
